Blueprint Medicines Corp Stock
-
Your prediction
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | -4.050% | -2.632% | 12.121% | -11.905% | -29.524% | -73.948% | -69.485% |
| Novocure Ltd | -4.220% | -7.250% | 7.700% | -65.719% | -63.977% | -85.051% | -92.101% |
| Iovance Biotherapeutics Inc. | 1.750% | 10.609% | 2.807% | -71.249% | -68.976% | -64.842% | -94.317% |
News
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
For the second quarter in a row, artificial intelligence (AI) tech stock Pegasystems (NASDAQ: PEGA) crushed expectations.
Shares soared 14% on July 22 as the company eclipsed Wall Street

